利用胎儿血红蛋白参数预测镰状细胞病的临床严重程度:坦桑尼亚队列的回顾性研究。

IF 2.1 Q3 HEMATOLOGY
Journal of Blood Medicine Pub Date : 2025-07-19 eCollection Date: 2025-01-01 DOI:10.2147/JBM.S493425
Hadiya M Haji, Florence Urio, Siana Nkya, Clara Chamba, Ahlam Nasser, Magdalena Lyimo, Mwashungi Ally, William Mawalla, Agnes Jonathan, Benson Kidenya, Ritah Mutagonda, Lulu Chirande, Paschal Ruggajo, Emmanuela Ambrose, Emmy Metta, Emmanuel Balandya, Julie Makani
{"title":"利用胎儿血红蛋白参数预测镰状细胞病的临床严重程度:坦桑尼亚队列的回顾性研究。","authors":"Hadiya M Haji, Florence Urio, Siana Nkya, Clara Chamba, Ahlam Nasser, Magdalena Lyimo, Mwashungi Ally, William Mawalla, Agnes Jonathan, Benson Kidenya, Ritah Mutagonda, Lulu Chirande, Paschal Ruggajo, Emmanuela Ambrose, Emmy Metta, Emmanuel Balandya, Julie Makani","doi":"10.2147/JBM.S493425","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fetal hemoglobin (HbF) is found at a measurable amount in red blood cells (RBCs) called F cells. High fetal hemoglobin (HbF) levels are linked with milder forms of sickle cell disease (SCD). However, some patients with high HbF levels still have severe symptoms. This variability has been associated with HbF per F cell (HbF/F cell) concentration; thus, it is hypothesized that high HbF/F cell (≥10 pg) is crucial in determining SCD disease severity rather than the overall HbF and F cell levels. This study assessed the utility of these three HbF parameters as predictors of SCD clinical events in Tanzania.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at Muhimbili University of Health and Allied Sciences, involving 92 SCD individuals aged ≥6 years, not on hydroxyurea, between September 2022 and February 2023. Data was collected from the Sickle Pan-African Research Consortium (SPARCO)-Tanzania registry. HbF/F cell was calculated as: HbF/F cell = (HbF% × MCH pg)/F cell%. STATA version 15 was used to analyze the association between HbF parameters and clinical events measured by ordinal logistic regression. A p-value <0.05 was considered statistically significant.</p><p><strong>Results: </strong>Of the 92 SCD participants, the median age was 16 (IQR: 10-21) years, 53 (57.6%) were below 18 years, and males were 48 (52.2%). Eighty-two patients (89.1%) had HbF/F cells below 10pg. Males had significantly higher HbF/F cell levels with a median of 6.4 (IQR: 4.3-9.5) pg compared to females 5.3 (IQR: 3.5-6.5) pg (p-value = 0.004). Although, we did not observe a statistically significant association between HbF/F cell with clinical parameters, increased HbF and F cell percentages correlated with reduced odds of multiple blood transfusions by 11% (p-value = 0.016) and 3% (p-value = 0.020), respectively.</p><p><strong>Conclusion: </strong>In this cohort, HbF and F cell levels remain important predictors of disease severity, as higher levels predicted reduced requirement for multiple blood transfusions in SCD patients, while HbF/F cells did not correlate with SCD clinical events.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"321-330"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285873/pdf/","citationCount":"0","resultStr":"{\"title\":\"Utilization of Fetal Hemoglobin Parameters in Predicting Clinical Severity of Sickle Cell Disease: Retrospective Study From a Tanzanian Cohort.\",\"authors\":\"Hadiya M Haji, Florence Urio, Siana Nkya, Clara Chamba, Ahlam Nasser, Magdalena Lyimo, Mwashungi Ally, William Mawalla, Agnes Jonathan, Benson Kidenya, Ritah Mutagonda, Lulu Chirande, Paschal Ruggajo, Emmanuela Ambrose, Emmy Metta, Emmanuel Balandya, Julie Makani\",\"doi\":\"10.2147/JBM.S493425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Fetal hemoglobin (HbF) is found at a measurable amount in red blood cells (RBCs) called F cells. High fetal hemoglobin (HbF) levels are linked with milder forms of sickle cell disease (SCD). However, some patients with high HbF levels still have severe symptoms. This variability has been associated with HbF per F cell (HbF/F cell) concentration; thus, it is hypothesized that high HbF/F cell (≥10 pg) is crucial in determining SCD disease severity rather than the overall HbF and F cell levels. This study assessed the utility of these three HbF parameters as predictors of SCD clinical events in Tanzania.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at Muhimbili University of Health and Allied Sciences, involving 92 SCD individuals aged ≥6 years, not on hydroxyurea, between September 2022 and February 2023. Data was collected from the Sickle Pan-African Research Consortium (SPARCO)-Tanzania registry. HbF/F cell was calculated as: HbF/F cell = (HbF% × MCH pg)/F cell%. STATA version 15 was used to analyze the association between HbF parameters and clinical events measured by ordinal logistic regression. A p-value <0.05 was considered statistically significant.</p><p><strong>Results: </strong>Of the 92 SCD participants, the median age was 16 (IQR: 10-21) years, 53 (57.6%) were below 18 years, and males were 48 (52.2%). Eighty-two patients (89.1%) had HbF/F cells below 10pg. Males had significantly higher HbF/F cell levels with a median of 6.4 (IQR: 4.3-9.5) pg compared to females 5.3 (IQR: 3.5-6.5) pg (p-value = 0.004). Although, we did not observe a statistically significant association between HbF/F cell with clinical parameters, increased HbF and F cell percentages correlated with reduced odds of multiple blood transfusions by 11% (p-value = 0.016) and 3% (p-value = 0.020), respectively.</p><p><strong>Conclusion: </strong>In this cohort, HbF and F cell levels remain important predictors of disease severity, as higher levels predicted reduced requirement for multiple blood transfusions in SCD patients, while HbF/F cells did not correlate with SCD clinical events.</p>\",\"PeriodicalId\":15166,\"journal\":{\"name\":\"Journal of Blood Medicine\",\"volume\":\"16 \",\"pages\":\"321-330\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285873/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Blood Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/JBM.S493425\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/JBM.S493425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:胎儿血红蛋白(HbF)在称为F细胞的红细胞(rbc)中有可测量的量。高胎儿血红蛋白(HbF)水平与轻度镰状细胞病(SCD)有关。然而,一些HbF水平高的患者仍然有严重的症状。这种可变性与每F细胞HbF (HbF/F细胞)浓度有关;因此,假设高HbF/F细胞(≥10 pg)是决定SCD疾病严重程度的关键,而不是总体HbF和F细胞水平。本研究评估了这三个HbF参数作为坦桑尼亚SCD临床事件预测因子的效用。方法:2022年9月至2023年2月,在Muhimbili卫生与相关科学大学进行了一项回顾性队列研究,涉及92名年龄≥6岁的SCD患者,未服用羟基脲。数据是从镰刀泛非研究联盟(SPARCO)-坦桑尼亚登记处收集的。HbF/F细胞计算公式为:HbF/F细胞= (HbF% × MCH pg)/F细胞%。使用STATA version 15分析HbF参数与有序逻辑回归测量的临床事件之间的相关性。p值结果:在92名SCD参与者中,年龄中位数为16岁(IQR: 10-21), 53名(57.6%)年龄在18岁以下,男性48名(52.2%)。82例患者(89.1%)HbF/F细胞低于10pg。男性的HbF/F细胞水平显著高于女性,中位值为6.4 (IQR: 4.3-9.5) pg,而女性为5.3 (IQR: 3.5-6.5) pg (p值= 0.004)。虽然我们没有观察到HbF/F细胞与临床参数之间有统计学意义的关联,但HbF和F细胞百分比的增加与多次输血几率的降低相关,分别为11% (p值= 0.016)和3% (p值= 0.020)。结论:在该队列中,HbF和F细胞水平仍然是疾病严重程度的重要预测指标,因为较高的水平预测SCD患者多次输血需求降低,而HbF/F细胞与SCD临床事件无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Utilization of Fetal Hemoglobin Parameters in Predicting Clinical Severity of Sickle Cell Disease: Retrospective Study From a Tanzanian Cohort.

Background: Fetal hemoglobin (HbF) is found at a measurable amount in red blood cells (RBCs) called F cells. High fetal hemoglobin (HbF) levels are linked with milder forms of sickle cell disease (SCD). However, some patients with high HbF levels still have severe symptoms. This variability has been associated with HbF per F cell (HbF/F cell) concentration; thus, it is hypothesized that high HbF/F cell (≥10 pg) is crucial in determining SCD disease severity rather than the overall HbF and F cell levels. This study assessed the utility of these three HbF parameters as predictors of SCD clinical events in Tanzania.

Methods: A retrospective cohort study was conducted at Muhimbili University of Health and Allied Sciences, involving 92 SCD individuals aged ≥6 years, not on hydroxyurea, between September 2022 and February 2023. Data was collected from the Sickle Pan-African Research Consortium (SPARCO)-Tanzania registry. HbF/F cell was calculated as: HbF/F cell = (HbF% × MCH pg)/F cell%. STATA version 15 was used to analyze the association between HbF parameters and clinical events measured by ordinal logistic regression. A p-value <0.05 was considered statistically significant.

Results: Of the 92 SCD participants, the median age was 16 (IQR: 10-21) years, 53 (57.6%) were below 18 years, and males were 48 (52.2%). Eighty-two patients (89.1%) had HbF/F cells below 10pg. Males had significantly higher HbF/F cell levels with a median of 6.4 (IQR: 4.3-9.5) pg compared to females 5.3 (IQR: 3.5-6.5) pg (p-value = 0.004). Although, we did not observe a statistically significant association between HbF/F cell with clinical parameters, increased HbF and F cell percentages correlated with reduced odds of multiple blood transfusions by 11% (p-value = 0.016) and 3% (p-value = 0.020), respectively.

Conclusion: In this cohort, HbF and F cell levels remain important predictors of disease severity, as higher levels predicted reduced requirement for multiple blood transfusions in SCD patients, while HbF/F cells did not correlate with SCD clinical events.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
94
审稿时长
16 weeks
期刊介绍: The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all topics pertaining to blood based medicine including but not limited to: Transfusion Medicine (blood components, stem cell transplantation, apheresis, gene based therapeutics), Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics, Immunohematology, Artificial and alternative blood based therapeutics, Hematology including disorders/pathology related to leukocytes/immunology, red cells, platelets and hemostasis, Biotechnology/nanotechnology of blood related medicine, Legal aspects of blood medicine, Historical perspectives. Original research, short reports, reviews, case reports and commentaries are invited.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信